Obesity Pillars最新文献

{"title":"Stronger control of eating 3 months after sleeve gastrectomy predicts successful weight loss outcomes at one year","authors":"Ellina Lytvyak ,&nbsp;Amir Zarrinpar ,&nbsp;Cecilia Dalle Ore ,&nbsp;Euyhyun Lee ,&nbsp;Keila Yazdani-Boset ,&nbsp;Santiago Horgan ,&nbsp;Eduardo Grunvald","doi":"10.1016/j.obpill.2024.100111","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100111","url":null,"abstract":"<div><h3>Background</h3><p>Weight loss response to sleeve gastrectomy (SG) is variable and predicting the effectiveness of surgery is challenging and elusive. The aim of our study was to assess and quantify the association between eating control and weight loss outcomes and identify the control of eating (CoE) attributes during the early postoperative period that might predict good vs. poor response to SG at one year.</p></div><div><h3>Methods</h3><p>A prospective longitudinal cohort study using the Control of Eating Questionnaire (CoEQ) was designed as a series before and at 3-, 6-, and 12-months post-SG. Primary outcomes were changes in CoE attributes and percent of total weight loss (%TWL) 12-months post-surgery. Subjects were categorized based on %TWL as good (GR, ≥25 %) or poor responders (PR, &lt;25 %). A receiver operating characteristic and logistic regression analyses were performed.</p></div><div><h3>Results</h3><p>We included 41 participants (80.5% females, 51.2% Hispanic, mean age 41.7±10.6, median baseline body mass index (BMI) 43.6 kg/m² [range 35.2–66.3]) who completed the CoEQ at all four timepoints. The “Difficulty to control eating” score at 3 months revealed the highest area under the curve (AUC) (AUC 0.711; 95%CI 0.524–0.898; p=0.032). In a trade-off between a high Youden index and high sensitivity, the “Difficulty to control eating” score of 7 at 3 months was identified as the optimal cut-off for distinguishing between GRs and PRs. Score ≤7 at 3 months was strongly independently associated with a successful weight loss target of 25%TWL at one-year post-SG (Relative Risk 4.43; 95%CI 1.06–18.54; p=0.042).</p></div><div><h3>Conclusion</h3><p>“Difficulty to control eating” score at 3 months post-SG is an independent early predictor of optimal response (achieving a successful TWL target of ≥25 % at one-year post-SG). Our results support the utility of this easy-to-administer validated tool for predicting the effectiveness of SG and may assist in identifying individuals with suboptimal response early and helping them with interventions to attain optimal weight loss targets.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"11 ","pages":"Article 100111"},"PeriodicalIF":0.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000135/pdfft?md5=683e2eabbbb146969ab1f77cd4840471&pid=1-s2.0-S2667368124000135-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiating monogenic and syndromic obesities from polygenic obesity: Assessment, diagnosis, and management","authors":"Angela K. Fitch ,&nbsp;Sonali Malhotra ,&nbsp;Rushika Conroy","doi":"10.1016/j.obpill.2024.100110","DOIUrl":"10.1016/j.obpill.2024.100110","url":null,"abstract":"<div><h3>Background</h3><p>Obesity is a multifactorial neurohormonal disease that results from dysfunction within energy regulation pathways and is associated with increased morbidity, mortality, and reduced quality of life. The most common form is polygenic obesity, which results from interactions between multiple gene variants and environmental factors. Highly penetrant monogenic and syndromic obesities result from rare genetic variants with minimal environmental influence and can be differentiated from polygenic obesity depending on key symptoms, including hyperphagia; early-onset, severe obesity; and suboptimal responses to nontargeted therapies. Timely diagnosis of monogenic or syndromic obesity is critical to inform management strategies and reduce disease burden. We outline the physiology of weight regulation, role of genetics in obesity, and differentiating characteristics between polygenic and rare genetic obesity to facilitate diagnosis and transition toward targeted therapies.</p></div><div><h3>Methods</h3><p>In this narrative review, we focused on case reports, case studies, and natural history studies of patients with monogenic and syndromic obesities and clinical trials examining the efficacy, safety, and quality of life impact of nontargeted and targeted therapies in these populations. We also provide comprehensive algorithms for diagnosis of patients with suspected rare genetic causes of obesity.</p></div><div><h3>Results</h3><p>Patients with monogenic and syndromic obesities commonly present with hyperphagia (ie, pathologic, insatiable hunger) and early-onset, severe obesity, and the presence of hallmark characteristics can inform genetic testing and diagnostic approach. Following diagnosis, specialized care teams can address complex symptoms, and hyperphagia is managed behaviorally. Various pharmacotherapies show promise in these patient populations, including setmelanotide and glucagon-like peptide-1 receptor agonists.</p></div><div><h3>Conclusion</h3><p>Understanding the pathophysiology and differentiating characteristics of monogenic and syndromic obesities can facilitate diagnosis and management and has led to development of targeted pharmacotherapies with demonstrated efficacy for reducing body weight and hunger in the affected populations.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"11 ","pages":"Article 100110"},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000123/pdfft?md5=ef18eb01d9e247c0054d2b3730d24d2e&pid=1-s2.0-S2667368124000123-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140766442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Obesity pillars roundtable: Body mass index and body composition in black and female individuals. Race-relevant or racist? Sex-relevant or sexist?” [Obesity Pillars 4C (2022) 100044]","authors":"Harold Edward Bays ,&nbsp;Sylvia Gonsahn-Bollie ,&nbsp;Courtney Younglove ,&nbsp;Sean Wharton","doi":"10.1016/j.obpill.2024.100105","DOIUrl":"10.1016/j.obpill.2024.100105","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100105"},"PeriodicalIF":0.0,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266736812400007X/pdfft?md5=e2ec63f3922a3ed3a882c1af3a0d02b5&pid=1-s2.0-S266736812400007X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140281860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024","authors":"Harold Edward Bays,&nbsp;Carol Kirkpatrick,&nbsp;Kevin C. Maki,&nbsp;Peter P. Toth,&nbsp;Ryan T. Morgan,&nbsp;Justin Tondt,&nbsp;Sandra Michelle Christensen,&nbsp;Dave Dixon,&nbsp;Terry A. Jacobson","doi":"10.1016/j.obpill.2024.100108","DOIUrl":"10.1016/j.obpill.2024.100108","url":null,"abstract":"<div><h3>Background</h3><p>This joint expert review by the Obesity Medicine Association (OMA) and National Lipid Association (NLA) provides clinicians an overview of the pathophysiologic and clinical considerations regarding obesity, dyslipidemia, and cardiovascular disease (CVD) risk.</p></div><div><h3>Methods</h3><p>This joint expert review is based upon scientific evidence, clinical perspectives of the authors, and peer review by the OMA and NLA leadership.</p></div><div><h3>Results</h3><p>Among individuals with obesity, adipose tissue may store over 50% of the total body free cholesterol. Triglycerides may represent up to 99% of lipid species in adipose tissue. The potential for adipose tissue expansion accounts for the greatest weight variance among most individuals, with percent body fat ranging from less than 5% to over 60%. While population studies suggest a modest increase in blood low-density lipoprotein cholesterol (LDL-C) levels with excess adiposity, the adiposopathic dyslipidemia pattern most often described with an increase in adiposity includes elevated triglycerides, reduced high density lipoprotein cholesterol (HDL-C), increased non-HDL-C, elevated apolipoprotein B, increased LDL particle concentration, and increased small, dense LDL particles.</p></div><div><h3>Conclusions</h3><p>Obesity increases CVD risk, at least partially due to promotion of an adiposopathic, atherogenic lipid profile. Obesity also worsens other cardiometabolic risk factors. Among patients with obesity, interventions that reduce body weight and improve CVD outcomes are generally associated with improved lipid levels. Given the modest improvement in blood LDL-C with weight reduction in patients with overweight or obesity, early interventions to treat both excess adiposity and elevated atherogenic cholesterol (LDL-C and/or non-HDL-C) levels represent priorities in reducing the risk of CVD.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100108"},"PeriodicalIF":0.0,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266736812400010X/pdfft?md5=30611622cac9e760720255876287e7b2&pid=1-s2.0-S266736812400010X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140282296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presentation of a weight bias internalization tool for use in pregnancy and a call for future research: A commentary","authors":"Taniya S. Nagpal ,&nbsp;Nicole Pearce ,&nbsp;Kristi B. Adamo","doi":"10.1016/j.obpill.2024.100107","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100107","url":null,"abstract":"<div><h3>Background</h3><p>Emerging evidence has shown that weight stigma is a concern during pregnancy, with several studies documenting common sources including healthcare, the media and interpersonal networks. Experiencing weight stigma may lead to weight bias internalization (WBI), whereby individuals accept and self-direct negative weight-related stereotypes, and limited research has assessed this in the context of pregnancy. Pregnancy is unique in terms of weight changes as many individuals will experience gestational weight gain (GWG). Accordingly, a WBI tool that accounts for GWG may be a more population-specific resource to use.</p></div><div><h3>Methods</h3><p>This commentary presents a pregnancy-specific WBI tool that accounts for GWG. The validated Adult WBI scale was modified to include ‘pregnancy weight gain’. This commentary also presents a brief summary of research that has assessed WBI in pregnancy and recommendations for future work.</p></div><div><h3>Results</h3><p>Recommended future work includes validation of the pregnancy-specific WBI tool and prospective examinations of weight stigma and WBI in pregnancy and implications on maternal and newborn outcomes.</p></div><div><h3>Conclusion</h3><p>Ultimately this research may inform development of interventions and resources to mitigate weight stigma and WBI in pregnancy and overall may contribute to improving prenatal outcomes and experiences.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100107"},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000093/pdfft?md5=9573824bef1ff7702c798c57ee74ea4b&pid=1-s2.0-S2667368124000093-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140141402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight-centric prevention of cancer","authors":"Diego Anazco ,&nbsp;Andres Acosta ,&nbsp;Elizabeth J. Cathcart-Rake ,&nbsp;Stacy D. D'Andre ,&nbsp;Maria D. Hurtado","doi":"10.1016/j.obpill.2024.100106","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100106","url":null,"abstract":"<div><h3>Background</h3><p>The link between excess adiposity and carcinogenesis has been well established for multiple malignancies, and cancer is one of the main contributors to obesity-related mortality. The potential role of different weight-loss interventions on cancer risk modification has been assessed, however, its clinical implications remain to be determined. In this clinical review, we present the data assessing the effect of weight loss interventions on cancer risk.</p></div><div><h3>Methods</h3><p>In this clinical review, we conducted a comprehensive search of relevant literature using MEDLINE, Embase, Web of Science, and Google Scholar databases for relevant studies from inception to January 20, 2024. In this clinical review, we present systematic reviews and meta-analysis, randomized clinical trials, and prospective and retrospective observational studies that address the effect of different treatment modalities for obesity in cancer risk. In addition, we incorporate the opinions from experts in the field of obesity medicine and oncology regarding the potential of weight loss as a preventative intervention for cancer.</p></div><div><h3>Results</h3><p>Intentional weight loss achieved through different modalities has been associated with a reduced cancer incidence. To date, the effect of weight loss on the postmenopausal women population has been more widely studied, with multiple reports indicating a protective effect of weight loss on hormone-dependent malignancies. The effect of bariatric interventions as a protective intervention for cancer has been studied extensively, showing a significant reduction in cancer incidence and mortality, however, data for the effect of bariatric surgery on certain specific types of cancer is conflicting or limited.</p></div><div><h3>Conclusion</h3><p>Medical nutrition therapy, exercise, antiobesity medication, and bariatric interventions, might lead to a reduction in cancer risk through weight loss-dependent and independent factors. Further evidence is needed to better determine which population might benefit the most, and the amount of weight loss required to provide a clinically significant preventative effect.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100106"},"PeriodicalIF":0.0,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000081/pdfft?md5=e755674535ec16622e68e439c1ba90c2&pid=1-s2.0-S2667368124000081-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140063300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: A narrative review","authors":"Dionysios V. Chartoumpekis ,&nbsp;Evagelia E. Habeos ,&nbsp;Aristea Psilopanagioti","doi":"10.1016/j.obpill.2024.100104","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100104","url":null,"abstract":"<div><h3>Background</h3><p>Hypothalamic obesity represents a clinical condition within the broader spectrum of obesity that frequently eludes detection and appropriate diagnosis. This subset of obesity is characterized by a dearth of established predictive markers and a paucity of standardized therapeutic protocols. The advent and rising prominence of glucagon-like peptide-1 (GLP-1) receptor agonists in the obesity treatment landscape present novel therapeutic avenues for hypothalamic obesity management. Nonetheless, critical inquiries persist concerning the efficacy of GLP-1 receptor (GLP-1R) agonists in this context, particularly regarding their central mechanisms of action and specific impact on hypothalamic obesity.</p></div><div><h3>Methods</h3><p>In this narrative review, we concentrate on analyzing research papers that delineate the detection and function of GLP-1 receptors across various hypothalamic and cerebral regions. Additionally, we examine clinical research papers and reports detailing the application of GLP-1 receptor agonists in treating hypothalamic obesity. Furthermore, we include a concise presentation of a clinical case from our unit for contextual understanding.</p></div><div><h3>Results</h3><p>Currently, the clinical evidence supporting the efficacy of GLP-1 receptor agonists in hypothalamic obesity, as well as the diverse characteristics of this obesity subtype, remains insufficient. Preliminary data suggest that GLP-1R agonists might offer an effective treatment option, albeit with variable outcomes, particularly in younger patient cohorts. From a mechanistic perspective, the presence of GLP-1 receptors in various hypothalamic and broader brain regions potentially underpins the efficacy of GLP-1R agonists, even in instances of hypothalamic damage. Nevertheless, additional research is imperative to establish the functional relevance of these receptors in said brain regions.</p></div><div><h3>Conclusion</h3><p>GLP-1R agonists represent a potential therapeutic option for patients with hypothalamic obesity. However, further clinical and basic/translational research is essential to validate the efficacy of these drugs across different presentations of hypothalamic obesity and to understand the functionality of GLP-1R in the diverse brain regions where they are expressed.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100104"},"PeriodicalIF":0.0,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000068/pdfft?md5=99a0c6546e411fd1fa3fe05da8516265&pid=1-s2.0-S2667368124000068-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140024290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future of Obesity Medicine: Fearless 5-year Predictions for 2029 by Obesity Medicine Association Committee Chairs","authors":"Harold Bays","doi":"10.1016/j.obpill.2024.100102","DOIUrl":"10.1016/j.obpill.2024.100102","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100102"},"PeriodicalIF":0.0,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000044/pdfft?md5=0a08bdc874c99856dc09667843c5a3c2&pid=1-s2.0-S2667368124000044-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact Of body Mass Index on Cardiopulmonary Outcomes of COVID-19 Hospitalizations Complicated by Severe Sepsis","authors":"Sivaram Neppala ,&nbsp;Himaja Dutt Chigurupati ,&nbsp;Nikhilender Nag Mopuru ,&nbsp;Naga Ruthvika Alle ,&nbsp;Alpha James ,&nbsp;Ami Bhalodia ,&nbsp;Sajida Shaik ,&nbsp;Revanth Reddy Bandaru ,&nbsp;Athmananda Nanjundappa ,&nbsp;Praveena Sunkara ,&nbsp;Jyotsna Gummadi ,&nbsp;Rupak Desai","doi":"10.1016/j.obpill.2024.100101","DOIUrl":"10.1016/j.obpill.2024.100101","url":null,"abstract":"<div><h3>Background</h3><p>Body Mass Index (BMI) has a significant impact on Coronavirus disease (COVID-19) patient outcomes; however, major adverse cardiac and cerebrovascular outcomes in patients with severe sepsis have been poorly understood. Our study aims to explore and provide insight into its association.</p></div><div><h3>Methods</h3><p>This is an observational study looking at the impact of BMI on COVID-19-severe sepsis hospitalizations. The primary outcomes are adjusted odds of all-cause in-hospital mortality, respiratory failure, and major adverse cardiac and cerebrovascular events (MACCE), which include acute myocardial infarction, cardiac arrest, and acute ischemic stroke. The secondary outcome was healthcare resource utilization. Coexisting comorbidities and patient features were adjusted with multivariable regression analyses.</p></div><div><h3>Results</h3><p>Of 51,740 patients with severe COVID-19-sepsis admissions, 11.4% were overweight, 24.8% had Class I obesity (BMI 30–34.9), 19.8% had Class II obesity (BMI 35–39.9), and 43.9% had the categorization of Class III obesity (BMI &gt;40) cohorts with age&gt;18 years. The odds of MACCE in patients with class II obesity and class III obesity (OR 1.09 and 1.54; 95CI 0.93–1.29 and 1.33–1.79) were significantly higher than in overweight (p &lt; 0.001). Class I, Class II, and Class III patients with obesity revealed lower odds of respiratory failure compared to overweight (OR 0.89, 0.82, and 0.82; 95CI 0.75–1.05, 0.69–0.97, and 0.70–0.97), but failed to achieve statistical significance (p = 0.079). On multivariable regression analysis, all-cause in-hospital mortality revealed significantly higher odds in patients with Class III obesity, Class II, and Class I (OR 1.56, 1.17, and 1.06; 95CI 1.34–1.81, 0.99–1.38, and 0.91–1.24) vs. overweight patients (p &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>Patients with Class II and Class III obesity had significantly higher odds of MACCE and in-hospital mortality in COVID-19-severe sepsis admissions.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"10 ","pages":"Article 100101"},"PeriodicalIF":0.0,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368124000032/pdfft?md5=eb4ad92f198389c7f9c1186adcb2e3e4&pid=1-s2.0-S2667368124000032-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139873065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact Of body Mass Index on Cardiopulmonary Outcomes of COVID-19 Hospitalizations Complicated by Severe Sepsis","authors":"Sivaram Neppala, H. Chigurupati, Nikhilender Nag Mopuru, Naga Ruthvika Alle, Alpha James, Ami Bhalodia, Sajida Shaik, Revanth Reddy Bandaru, Athmananda Nanjundappa, P. Sunkara, Jyotsna Gummadi, Rupak Desai","doi":"10.1016/j.obpill.2024.100101","DOIUrl":"https://doi.org/10.1016/j.obpill.2024.100101","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"174 S400","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139812778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}